These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 34508328)

  • 1. The Efficacy of Penicillins with β-lactamase Inhibitor or Cefmetazole against Pneumonia in which ESBL-Producing Bacteria were Isolated from Sputum.
    Goto A; Komiya K; Hiramatsu K; Kadota JI
    Infect Chemother; 2021 Sep; 53(3):562-564. PubMed ID: 34508328
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply: The Efficacy of Penicillins with β-lactamase Inhibitor or Cefmetazole against Pneumonia in which ESBL-Producing Bacteria were Isolated from Sputum.
    Kang CI
    Infect Chemother; 2021 Sep; 53(3):565-567. PubMed ID: 34508326
    [No Abstract]   [Full Text] [Related]  

  • 3. Isolation of ESBL-producing Bacteria from Sputum in Community-acquired Pneumonia or Healthcare-associated Pneumonia Does Not Indicate the Need for Antibiotics with Activity against This Class.
    Horie H; Ito I; Konishi S; Yamamoto Y; Yamamoto Y; Uchida T; Ohtani H; Yoshida Y
    Intern Med; 2018 Feb; 57(4):487-495. PubMed ID: 29021461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefmetazole for extended-spectrum β-lactamase-producing Enterobacteriaceae in pediatric pyelonephritis.
    Araki K; Fukuoka K; Higuchi H; Aizawa Y; Horikoshi Y
    Pediatr Int; 2019 Jun; 61(6):572-577. PubMed ID: 30908807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum β-lactamase and plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae.
    Matsumura Y; Yamamoto M; Nagao M; Tanaka M; Takakura S; Ichiyama S
    Diagn Microbiol Infect Dis; 2016 Apr; 84(4):322-7. PubMed ID: 26782634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Doi A; Shimada T; Harada S; Iwata K; Kamiya T
    Int J Infect Dis; 2013 Mar; 17(3):e159-63. PubMed ID: 23140947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To Use, or Not to Use Carbapenem When Extended-spectrum β-lactamase (ESBL)-producing Bacteria Are Isolated from Sputum Cultures, That Is the Question.
    Miki M
    Intern Med; 2018 Feb; 57(4):455-456. PubMed ID: 29269652
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole.
    Horie A; Nariai A; Katou F; Abe Y; Saito Y; Koike D; Hirade T; Ito T; Wakuri M; Fukuma A
    Clin Exp Nephrol; 2019 Nov; 23(11):1306-1314. PubMed ID: 31428892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems.
    Fukuchi T; Iwata K; Kobayashi S; Nakamura T; Ohji G
    BMC Infect Dis; 2016 Aug; 16(1):427. PubMed ID: 27538488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of Antibiotics for the Treatment of Bacteremia Due to Extended-spectrum β-Lactamase-producing Escherichia coli].
    Sugawara T; Murakami N; Uetake N; Hiraki K
    Yakugaku Zasshi; 2015; 135(6):829-33. PubMed ID: 26028418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates].
    Xiong Z; Zhu D; Zhang Y; Wang F
    Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1476-9. PubMed ID: 12509910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antibacterial activity of beta-lactam antibiotics against extended-spectrum beta-lactamase producing bacteria].
    Kuga A; Yano H; Okamoto R; Sato Y; Miyata A; Inoue M
    Jpn J Antibiot; 1999 Sep; 52(9):585-94. PubMed ID: 10746193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-β-lactamase-producing Escherichia coli bacteremia.
    Matsumura Y; Yamamoto M; Nagao M; Komori T; Fujita N; Hayashi A; Shimizu T; Watanabe H; Doi S; Tanaka M; Takakura S; Ichiyama S
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5107-13. PubMed ID: 26100708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. beta-Lactamase-mediated inactivation and efficacy of cefazolin and cefmetazole in Staphylococcus aureus abscesses.
    Fields MT; Herndon BL; Bamberger DM
    Antimicrob Agents Chemother; 1993 Feb; 37(2):203-6. PubMed ID: 8452349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical analysis of nosocomial infection of extended spectrum beta-lactamase-producing bacteria].
    Cao B; Wang H; Chen M
    Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):581-4. PubMed ID: 11758235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended spectrum beta-lactamase and metallo beta-lactamase production among Escherichia coli and Klebsiella pneumoniae isolated from different clinical samples in a tertiary care hospital in Kathmandu, Nepal.
    Nepal K; Pant ND; Neupane B; Belbase A; Baidhya R; Shrestha RK; Lekhak B; Bhatta DR; Jha B
    Ann Clin Microbiol Antimicrob; 2017 Sep; 16(1):62. PubMed ID: 28927454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spreading of extended-spectrum β-lactamase-producing Escherichia coli ST131 and Klebsiella pneumoniae ST11 in patients with pneumonia: a molecular epidemiological study.
    Liu J; Du SX; Zhang JN; Liu SH; Zhou YY; Wang XR
    Chin Med J (Engl); 2019 Aug; 132(16):1894-1902. PubMed ID: 31408445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility of major pathogens of orofacial odontogenic infections to 11 beta-lactam antibiotics.
    Kuriyama T; Karasawa T; Nakagawa K; Nakamura S; Yamamoto E
    Oral Microbiol Immunol; 2002 Oct; 17(5):285-9. PubMed ID: 12354209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective evaluation of appropriate dosing of cefmetazole for invasive urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli.
    Hamada Y; Matsumura Y; Nagashima M; Akazawa T; Doi Y; Hayakawa K
    J Infect Chemother; 2021 Nov; 27(11):1602-1606. PubMed ID: 34348852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors of nosocomial infection with extended-spectrum beta-lactamase-producing bacteria in a neonatal intensive care unit in China.
    Huang Y; Zhuang S; Du M
    Infection; 2007 Oct; 35(5):339-45. PubMed ID: 17721736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.